Next Article in Journal
Impact of Isolated High Home Systolic Blood Pressure and Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus: A 5-Year Prospective Cohort Study
Next Article in Special Issue
Noncompaction Cardiomyopathy—History and Current Knowledge for Clinical Practice
Previous Article in Journal
Possible Earlier Diagnosis of Ulcerative Colitis-Associated Neoplasia: A Retrospective Analysis of Interval Cases during Surveillance
Previous Article in Special Issue
Role of Provocable Brugada ECG Pattern in The Correct Risk Stratification for Major Arrhythmic Events
 
 
Article

Nucleoside Analogue Reverse Transcriptase Inhibitors Improve Clinical Outcome in Transcriptional Active Human Parvovirus B19-Positive Patients

1
Institute of Cardiac Diagnostics and Therapy, 12203 Berlin, Germany
2
Department of Cardiology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, 12200 Berlin, Germany
3
Institute of Tropical Medicine, University of Tübingen, 72074 Tübingen, Germany
4
Department of Internal Medicine and Cardiology, Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany
5
DZHK (German Centre for Cardiovascular Research), Berlin, Germany
6
Department of Cardiology, Medical University Graz, 8036 Graz, Austria
*
Author to whom correspondence should be addressed.
Academic Editor: Stefan Peters
J. Clin. Med. 2021, 10(9), 1928; https://doi.org/10.3390/jcm10091928
Received: 16 March 2021 / Revised: 24 April 2021 / Accepted: 25 April 2021 / Published: 29 April 2021
(This article belongs to the Collection Cardiomyopathies: Current Treatment and Future Options)
Human parvovirus B19 (B19V) is the predominant cardiotropic virus associated with dilated inflammatory cardiomyopathy (DCMi). Transcriptionally active cardiotropic B19V infection is clinically relevant and triggers adverse long-term mortality. During the study; we evaluated whether antiviral treatment with the nucleoside analogue telbivudine (LTD) is effective in suppressing transcriptional active B19V in endomyocardial biopsies (EMBs) of B19V positive patients and improving clinical outcomes. Seventeen B19V-positive patients (13 male; mean age 45.7 ± 13.9 years; mean left ventricular ejection fraction (LVEF) 37.7 ± 13.5%) with positive B19V DNA and transcriptional activity (B19V mRNA) in EMBs were treated with 600 mg/d LTD over a period of six months. Patients underwent EMBs before and after termination of the LTD treatment. B19V RNA copy numbers remained unchanged in 3/17 patients (non-responder) and declined or disappeared completely in the remaining 14/17 patients (responder) (p ≤ 0.0001). Notably; LVEF improvement was more significant in patients who reduced or lost B19V RNA (responder; p = 0.02) in contrast to non-responders (p = 0.7). In parallel; responder patients displayed statistically significant improvement in quality of life (QoL) questionnaires (p = 0.03) and dyspnea on exertion (p = 0.0006), reflecting an improvement in New York Heart Association (NYHA) Classification (p = 0.001). Our findings demonstrated for the first time that suppression of B19V transcriptional activity by LTD treatment improved hemodynamic and clinical outcome significantly. Thus; the present study substantiates the clinical relevance of detecting B19V transcriptional activity of the myocardium. View Full-Text
Keywords: parvovirus B19; dilated inflammatory cardiomyopathy; telbivudine parvovirus B19; dilated inflammatory cardiomyopathy; telbivudine
Show Figures

Figure 1

MDPI and ACS Style

Schultheiss, H.-P.; Bock, T.; Pietsch, H.; Aleshcheva, G.; Baumeier, C.; Fruhwald, F.; Escher, F. Nucleoside Analogue Reverse Transcriptase Inhibitors Improve Clinical Outcome in Transcriptional Active Human Parvovirus B19-Positive Patients. J. Clin. Med. 2021, 10, 1928. https://doi.org/10.3390/jcm10091928

AMA Style

Schultheiss H-P, Bock T, Pietsch H, Aleshcheva G, Baumeier C, Fruhwald F, Escher F. Nucleoside Analogue Reverse Transcriptase Inhibitors Improve Clinical Outcome in Transcriptional Active Human Parvovirus B19-Positive Patients. Journal of Clinical Medicine. 2021; 10(9):1928. https://doi.org/10.3390/jcm10091928

Chicago/Turabian Style

Schultheiss, Heinz-Peter, Thomas Bock, Heiko Pietsch, Ganna Aleshcheva, Christian Baumeier, Friedrich Fruhwald, and Felicitas Escher. 2021. "Nucleoside Analogue Reverse Transcriptase Inhibitors Improve Clinical Outcome in Transcriptional Active Human Parvovirus B19-Positive Patients" Journal of Clinical Medicine 10, no. 9: 1928. https://doi.org/10.3390/jcm10091928

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop